Nimbus hopes to strike thrice

Deals with Gilead and Takeda have established Nimbus Therapeutics as a successful negotiator. The former picked up Nimbus's Nash contender NDI-010976, now known as firsocostat, for $400m up front in 2016, and last year the Japanese company bagged the Tyk2 inhibitor NDI-034858 for a chunky $4bn.